LRRK2 Knockout Mice Have an Intact

Total Page:16

File Type:pdf, Size:1020Kb

LRRK2 Knockout Mice Have an Intact Hinkle et al. Molecular Neurodegeneration 2012, 7:25 http://www.molecularneurodegeneration.com/content/7/1/25 RESEARCH ARTICLE Open Access LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors Kelly M Hinkle1†, Mei Yue1†, Bahareh Behrouz1, Justus C Dächsel1, Sarah J Lincoln1, Erin E Bowles1, Joel E Beevers1, Brittany Dugger1, Beate Winner2, Iryna Prots2, Caroline B Kent1, Kenya Nishioka1, Wen-Lang Lin1, Dennis W Dickson1, Christopher J Janus3, Matthew J Farrer1,4 and Heather L Melrose1* Abstract Mutations in the LRRK2 gene are the most common cause of genetic Parkinson’s disease. Although the mechanisms behind the pathogenic effects of LRRK2 mutations are still not clear, data emerging from in vitro and in vivo models suggests roles in regulating neuronal polarity, neurotransmission, membrane and cytoskeletal dynamics and protein degradation. We created mice lacking exon 41 that encodes the activation hinge of the kinase domain of LRRK2. We have performed a comprehensive analysis of these mice up to 20 months of age, including evaluation of dopamine storage, release, uptake and synthesis, behavioral testing, dendritic spine and proliferation/neurogenesis analysis. Our results show that the dopaminergic system was not functionally comprised in LRRK2 knockout mice. However, LRRK2 knockout mice displayed abnormal exploratory activity in the open-field test. Moreover, LRRK2 knockout mice stayed longer than their wild type littermates on the accelerated rod during rotarod testing. Finally, we confirm that loss of LRRK2 caused degeneration in the kidney, accompanied by a progressive enhancement of autophagic activity and accumulation of autofluorescent material, but without evidence of biphasic changes. Keywords: Parkinson’s disease, Knockout, Dopamine, Microdialysis, Neuropathology, Open-field, Motor co- ordination, Kidney, Autophagy Background expressing physiological levels of LRRK2 has led to an Mutations in the LRRK2 gene, originally described in 2004, emerging theme that aberrant LRRK2 leads to subtle have now emerged as the most important genetic finding in alterations in dopamine neurotransmission, albeit in the Parkinson’s disease (PD) [1,2]. Incredibly, the most com- absence of dopaminergic neuronal loss [11]. Imaging mon mutation LRRK2 G2019S accounts for up to 40 % of studies in asymptomatic PD patients show the earliest Parkinsonism in populations of certain ethnic descent [3-5]. detectable changes occur in the dopamine transporter LRRK2 mutations also account for around 2% of sporadic and the same holds true for asymptomatic LRRK2 Parkinsonism and two risk factors have been identified in [12,13] and SNCA (alpha-synuclein) patients [14-16]. Asian populations [6-9]. LRRK2-associated PD is a late Neurotransmission alterations in mutant LRRK2 models onset disease and in general the disease resembles idio- may be similar to early preclinical events, suggesting an pathic PD both clinically and pathologically. early involvement in dopamine dysfunction. LRRK2 has been linked to neurite outgrowth, vesicular The expression profile of LRRK2 mRNA suggests that trafficking, protein translation and autophagy [10]. Ana- LRRK2 is unlikely to be an essential developmental pro- lysis of mutant transgenic and knock-in models tein [17]. In adult rodent brain, LRRK2 mRNA is found at highest levels in dopamine receptive areas particularly * Correspondence: [email protected] the striatum [18-22]. However, protein expression of † Equal contributors LRRK2 is abundant throughout the brain including the 1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA Full list of author information is available at the end of the article substantia nigra, striatum, hippocampus, thalamus, © 2012 Hinkle et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hinkle et al. Molecular Neurodegeneration 2012, 7:25 Page 2 of 17 http://www.molecularneurodegeneration.com/content/7/1/25 cerebellum and cortex [23] suggesting it may have a role the functional integrity of the nigro-striatal dopa- in multiple brain functions (i.e. memory, sensory, emo- minergic pathway. To determine if dopamine neurons or tion) and not just those involved in motor control. their processes were altered in the substantia nigra, we To further study the role of LRRK2 in the brain, we have performed stereological counts of tyrosine hydroxylase developed LRRK2 knockout mice by ablating exon 41 in (TH) positive neurons and dendrites in KO and WT the kinase domain of LRRK2. We have performed a com- mice aged 18–20 months. No differences in neuronal esti- prehensive analysis to study the effect of loss of LRRK2; mates were observed between KO mice (mean estimate ± this includes a thorough investigation of the dopaminergic SEM; 13,766 ± 471) compared to their WT littermates system, extensive behavioral tests to examine motor, co- (12,267 ± 481) (Figure 2A). Similarly, there were no differ- ordination and emotional behavior, as well as neuropatho- ences between dendritic estimates for WT (149,763 ± logical analyses. We find little evidence that loss of LRRK2 6213) and KO (153,873 ± 4351) (Figure 2B). Next, we impacts dopaminergic neurotransmission or striatal beha- examined dopamine axonal neurochemistry by analyzing viors, however we present data showing changes in the ex- total dopamine content in striatal lysates by HPLC from ploratory and motor co-ordination behaviors in these 10 month and 18 month KO mice and WT littermates mice. These findings may be an important consideration (Figure 2C-G, data shown only for 18 months) and found for future anti-LRRK2 therapies. dopamine and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) levels were Results equivalent in KO and WT animals at both time points. Generation of murine LRRK2 knockout mice Since total striatal dopamine includes dopamine that is The targeting strategy for generation of LRRK2 knockout stored, synthesized, released and taken up, we hypothe- (KO) mice is shown in Figure 1A. Homozygous mice sized that we may observe differences in KO mice by received from Ozgene PLC were bred to Jackson C57BL6/ investigating these mechanisms independently. First, we J mice and subsequent heterozygous offspring were bred performed microdialysis to measure extracellular release together to obtain wild type (WT), heterozygous (HET) of dopamine in vivo. Extracellular dopamine levels were and KO animals. Northern blotting analysis with a probe measured before and after KCl-evoked dopamine response designed to LRRK2 exon 24–27 confirmed the absence of in WT, HET and KO mice aged 3–4monthsofage the ~9 kb LRRK2 mRNA transcript in KO mice and a (Figure 2H). Baseline levels of dopamine were not found reduced transcript signal in the HET mice (Figure 1B). to differ between WT (0.13 ± 0.06 pg/μl), HET (0.15 ± Similarly, immunoblotting confirmed absence of LRRK2 0.06 pg/μl) or KO mice (0.16 ± 0.07 pg/μl). When post- protein band in the KO mice and a diminished signal in KCl dopamine levels were normalized to the average of HET mice (Figure 1C). Immunohistochemistry also their individual basal dopamine levels (i.e. % response) no revealed specific signal in the WT compared to KO significant differences were observed (Figure 2I). Next, we (Figure 1D). examined dopamine uptake in the WT, HET and KO mice To determine if any compensatory mRNA changes oc- using a radioactive uptake assay with [3H] dopamine. Up- curred in the paralog LRRK1, we used quantitative Taqman take was comparable across the three groups suggesting a assay with a probe to murine LRRK1 to compare WT, HET functionally intact dopamine transporter (Additional file and KO mice. No significant alterations in LRRK1 mRNA 2: Figure S2A). Concluding that release, storage and up- levels were observed in any of the brain regions tested. We take of dopamine appear to be normal, we then examined also checked mRNA levels of SNCA, MAPT or PARKIN D2-autoreceptor mediated synthesis and release, which is and found no differences (Additional file 1: Figure S1). one of the feedback mechanisms in the striatum. It is well LRRK2 KO mice were fertile and appeared to be healthy known that antagonizing pre-synaptic D2 autoreceptors from birth, with body weights comparable to WT litter- can remove this feedback inhibition and cause increased mates within the study period. HET x HET breedings synthesis as well as release of dopamine [24]. WT, HET yielded Mendelian ratios in line with expected inheritance and KO mice were treated with the D2 receptor antagon- (fromover70litters24.4%WT,51.6%HET,24%KO). ist raclopride, sacrificed 30 min later and HPLC analysis Subsequent characterization experiments were performed performed to quantify dopamine and metabolites. As to compare KO and WT mice at different aging time expected, dopamine turnover, as measured by the ratio of points. Due to animal costs and space restraints, we dopamine metabolites to stores of dopamine increased included a HET group in some, but not all, of these dramatically [One way ANOVA ps < 0.0001 for DOPAC/ analyses. dopamine and HVA/dopamine] following treatment with raclopride (Additional file 2: Figure S2B, C). However, Dopaminergic system characterization Tukey’s post hoc comparisons did not reveal differences in LRRK2 expression is normally found in high levels in the this response between WT, HET or KO mice, suggesting striatum so we reasoned that loss of LRRK2 may impact that autoreceptor-mediated feedback is normal in the Hinkle et al. Molecular Neurodegeneration 2012, 7:25 Page 3 of 17 http://www.molecularneurodegeneration.com/content/7/1/25 Figure 1 Generation and expression characterization of LRRK2 KO mice. (a) Schematic diagram (courtesy of Ozgene PLC) showing targeted locus. Exon 41 was flanked with LoxP sites to allow deletion with Cre recombinase. PKG-Neo-pA-SD-IS is Ozgene’s standard selection cassette and was inserted downstream of exon 41.
Recommended publications
  • The Cerebrospinal Fluid Homovanillic Acid Concentration in Patients with Parkinsonism Treated with L-Dopa
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.33.1.1 on 1 February 1970. Downloaded from J. NeuroL Neurosurg. Psychiat., 1970, 33, 1-6 The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa G. CURZON, R. B. GODWIN-AUSTEN, E. B. TOMLINSON, AND B. D. KANTAMANENI From the Institute ofNeurology, The National Hospital, Queen Square, London Almost all the dopamine in normal human brain is standing of the mechanism of action of L-dopa in contained in the basal ganglia and related structures Parkinsonism. (Bertler, 1961). Very low dopamine concentrations are present in the caudate nucleus, putamen, and METHODS substantia nigra of subjects with Parkinson's disease (Ehringer and Hornykiewicz, 1960; Hornykiewicz, Nine patients were studied. They all had been resident 1963; Bernheimer and Hornykiewicz, 1965). Lesions in a long-stay hospital for between three months and guest. Protected by copyright. seven years. They were selected from a population of in the substantia nigra have been considered chara- 24 patients suffering from Parkinsonism and were teristic of Parkinsonism (Hassler, 1938; Greenfield accepted for treatment only if their agreement were given and Bosanquet, 1953) and, therefore, the clinical after details of the treatment and investigation had been significance of these biochemical observations is explained. Patients were excluded from this trial if they increased by the finding that stereotactic lesions in the showed significant physical disability unrelated to substantia nigra of the rat or monkey cause depletion Parkinsonism. of dopamine in the caudate nucleus (Anden, Clinical assessment was carried out using a standard Carlsson, Dahlstrom, Fuxe, Hillarp, and Larsson, proforma of 57 items (Godwin-Austen et al., 1969).
    [Show full text]
  • Biogenic Amine Reference Materials
    Biogenic Amine reference materials Epinephrine (adrenaline), Vanillylmandelic acid (VMA) and homovanillic norepinephrine (noradrenaline) and acid (HVA) are end products of catecholamine metabolism. Increased urinary excretion of VMA dopamine are a group of biogenic and HVA is a diagnostic marker for neuroblastoma, amines known as catecholamines. one of the most common solid cancers in early childhood. They are produced mainly by the chromaffin cells in the medulla of the adrenal gland. Under The biogenic amine, serotonin, is a neurotransmitter normal circumstances catecholamines cause in the central nervous system. A number of disorders general physiological changes that prepare the are associated with pathological changes in body for fight-or-flight. However, significantly serotonin concentrations. Serotonin deficiency is raised levels of catecholamines and their primary related to depression, schizophrenia and Parkinson’s metabolites ‘metanephrines’ (metanephrine, disease. Serotonin excess on the other hand is normetanephrine, and 3-methoxytyramine) are attributed to carcinoid tumours. The determination used diagnostically as markers for the presence of of serotonin or its metabolite 5-hydroxyindoleacetic a pheochromocytoma, a neuroendocrine tumor of acid (5-HIAA) is a standard diagnostic test when the adrenal medulla. carcinoid syndrome is suspected. LGC Quality - ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Reference materials Product code Description Pack size Epinephrines and metabolites TRC-E588585 (±)-Epinephrine
    [Show full text]
  • 2018-PED Oncology
    Medical Guidelines Institute Pediatric Oncology Imaging Guidelines Version 10.1.2018 Medical Guidelines Institute Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) who may be able to provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT ® five digit codes, nomenclature and other data are copyright 2016 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2018-2019 Medical Guidelines Institute. All rights reserved. Pediatric Oncology Imaging Guidelines Abbreviations For Pediatric Oncology Imaging Guidelines........................ 3 PEDONC-1: General Guidelines.................................................................... 9 PEDONC-2: Screening Imaging in Cancer Predisposition Syndromes .... 22 PEDONC-3: Pediatric Leukemias ................................................................ 39 PEDONC-4: Pediatric CNS Tumors ............................................................ 45 PEDONC-5: Pediatric
    [Show full text]
  • Biochemical Procedures As Aids in Diagnosis of Different Forms of Cancer
    A n n a l s o f C l i n i c a l An d L a b o r a t o r y S c i e n c e , Vol. 4, No. 2 Copyright © 1974, Institute for Clinical Science Biochemical Procedures as Aids in Diagnosis of Different Forms of Cancer MORTON K. SCHWARTZ, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021 ABSTRACT The application of biochemical analyses as aids in the diagnosis of cancer is discussed with emphasis on the fact that biochemical testing is more useful in following the regression and progression of disease than in early initial diagnosis. The uses of biochemical analyses of metabolic degradation products, lipids, hormones and their receptors, enzymes, including isoenzymes, and trace metals are included. Introduction indicated in table I these include neuro­ Diagnostic procedures in cancer must be blastoma, pheochromocytoma, carcinoid, designed to achieve several purposes. They hepatocellular carcinoma, multiple mye­ must define the disease, describe its extent loma, osteogenic sarcoma and other osteo­ and be useful in following its progression blastic bone tumors. In these diseases, the or regression. For more than 75 years, in­ assay of the listed components is essential vestigators have searched for biochemical for confirmation of the diagnosis and in defects in cancer cells that could be ex­ following the response to therapy. ploited in diagnosis. Despite these long and continuing studies, few biochemical proce­ Serum Enzymes dures have been developed for early diag­ Historically, the biochemical procedure nosis of specific forms of cancer. The most used for the longest time as a diagnostic useful application of biochemical assays aid in cancer is acid phosphatase.
    [Show full text]
  • Use of Biomarkers in Screening for Cancer
    Michael J Duffy USE OF BIOMARKERS IN SCREENING FOR CANCER USE OF BIOMARKERS IN SCREENING FOR CANCER Michael J Duffy Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital, Dublin 4, UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland Correspondence Professor M J Duffy Dept of Nuclear Medicine St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland Tel No: 353‐1‐2094378 Fax No: 353‐1‐2696018 E‐mail: [email protected] Abstract Background: Screening for premalignant lesions or early invasive disease has the potential to reduce mortality from cancer. Potential screening tests for malignancy include measurement of (bio)markers. Content: The literature relevant to the use of biomarkers as screening tests for cancer was reviewed with particular attention given to systematic reviews, prospective randomised trials and guidelines published by Expert Panels. Because of their ease of measurement, several biomarkers have been evaluated or are currently undergoing evaluation as screening tests for early malignancy. These include the use of vanillymandelic acid and homovanillic acid in screening for neuroblastoma in newborn infants, AFP in screening for hepatocellular cancer in high‐risk subjects, CA 125 in combination with transvaginal ultrasound (TVU) in screening for ovarian cancer, PSA in screening for prostate cancer and fecal occult blood testing (FOBT) in screening for CRC. Of these markers, only the use of FOBT in screening for CRC has been shown to reduce mortality from cancer. Large randomized prospective trials are currently in progress aimed at evaluating the potential value of PSA screening in reducing mortality from prostate cancer and CA 125 in combination with TVU in reducing mortality form ovarian cancer.
    [Show full text]
  • The Role of Immunogenic Cell Death
    cancers Review Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death 1, 2, 1 3 4 Zahra Asadzadeh y, Elham Safarzadeh y, Sahar Safaei , Ali Baradaran , Ali Mohammadi , Khalil Hajiasgharzadeh 1 , Afshin Derakhshani 1 , Antonella Argentiero 5, Nicola Silvestris 5,6,* and Behzad Baradaran 1,7,* 1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, Iran; [email protected] (Z.A.); [email protected] (S.S.); [email protected] (K.H.); [email protected] (A.D.) 2 Department of Immunology and Microbiology, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil 5618985991, Iran; [email protected] 3 Research & Development Lab, BSD Robotics, 4500 Brisbane, Australia; [email protected] 4 Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark; [email protected] 5 IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, 70124 Bari, Italy; [email protected] 6 Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, 70124 Bari, Italy 7 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran * Correspondence: [email protected] (N.S.); [email protected] (B.B.); Tel.: +98-413-337-1440 (B.B.) The first two authors contributed equally to this work. y Received: 12 March 2020; Accepted: 17 April 2020; Published: 23 April 2020 Abstract: Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape.
    [Show full text]
  • A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma
    4 Vol. 10, 4–12, January 1, 2004 Clinical Cancer Research Review A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma Richard D. Riley,1 David Heney,2 reviews in the future. In particular, collaboration of cancer David R. Jones,1 Alex J. Sutton,1 research groups is needed to enable bigger sample sizes, Paul C. Lambert,1 Keith R. Abrams,1 standardize methods of analysis and reporting, and facilitate the pooling of individual patient data. Bridget Young,3 Alan J. Wailoo,4 and Susan A. Burchill5 Introduction Departments of 1Health Sciences, 2Medical Education, University of Leicester, Leicester; 3Department of Psychology, University of Hull, Neuroblastoma is a neuroblastic tumor of the primordial Hull; 4School of Health and Related Research, University of neural crest and is the most common extracranial solid tumor of Sheffield, Sheffield; and 5Cancer Research United Kingdom Clinical childhood, comprising between 8 and 10% of all childhood Centre, St. James’s University Hospital, Leeds, United Kingdom cancers. It is an enigmatic tumor demonstrating diverse clinical and biological characteristics and behavior (1). Tumors may regress spontaneously, reflecting induction of apoptosis or dif- Abstract ferentiation, or they may exhibit extremely malignant behavior Purpose: The aim of this study was to conduct a sys- with very low cure rates. The spectrum of clinical behavior tematic review, and where possible meta-analyses, of molec- suggests that genetic, biological, and morphological features ular and biological tumor markers described in neuroblas- may be useful markers to stratify children with this disease for toma, and to establish an evidence-based perspective on the most appropriate management.
    [Show full text]
  • Cis-3-O-P-Hydroxycinnamoyl Ursolic Acid Induced ROS-Dependent P53-Mediated Mitochondrial Apoptosis in Oral Cancer Cells
    Original Article Biomol Ther 27(1), 54-62 (2019) Cis-3-O-p-hydroxycinnamoyl Ursolic Acid Induced ROS-Dependent p53-Mediated Mitochondrial Apoptosis in Oral Cancer Cells Ching-Ying Wang1,†, Chen-Sheng Lin2,†, Chun-Hung Hua3,†, Yu-Jen Jou1, Chi-Ren Liao4, Yuan-Shiun Chang4, Lei Wan5, Su-Hua Huang6, Mann-Jen Hour7,* and Cheng-Wen Lin1,6,* 1Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, 2Division of Gastroenterology, Kuang Tien General Hospital, Taichung 43303, 3Department of Otolaryngology, China Medical University Hospital, Taichung 40447, 4Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 40402, 5Department of Medical Genetics and Medical Research, China Medical University Hospital, Taichung 40447, 6Department of Biotechnology, Asia University, Wufeng, Taichung 41357, 7School of Pharmacy, China Medical University, Taichung 40402, Taiwan Abstract Cis-3-O-p-hydroxycinnamoyl ursolic acid (HCUA), a triterpenoid compound, was purified from Elaeagnus oldhamii Maxim. This traditional medicinal plant has been used for treating rheumatoid arthritis and lung disorders as well as for its anti-inflammation and anticancer activities. This study aimed to investigate the anti-proliferative and apoptotic-inducing activities of HCUA in oral cancer cells. HCUA exhibited anti-proliferative activity in oral cancer cell lines (Ca9-22 and SAS cells), but not in normal oral fibroblasts. The inhibitory concentration of HCUA that resulted in 50% viability was 24.0 µM and 17.8 µM for Ca9-22 and SAS cells, respectively. Moreover, HCUA increased the number of cells in the sub-G1 arrest phase and apoptosis in a concentration- dependent manner in both oral cancer cell lines, but not in normal oral fibroblasts.
    [Show full text]
  • Plasma Free Metanephrines for Diagnosis of Neuroblastoma Patients
    Clinical Biochemistry 66 (2019) 57–62 Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Plasma free metanephrines for diagnosis of neuroblastoma patients T Sebastiano Barcoa,1, Iedan Verlyb,c,d,1, Maria Valeria Corriase, Stefania Sorrentinof, Massimo Contef, Gino Tripodia, Godelieve Tytgatb,c, André van Kuilenburgd, Maria van der Hamg, ⁎ Monique de Sain-van der Veldeng, Alberto Garaventaf, Giuliana Cangemia, a Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genoa, Italy b Department of Pediatric Oncology, Amsterdam UMC, Amsterdam, the Netherlands c Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands d Laboratory of Genetic Metabolic Disorders, Amsterdam UMC, Amsterdam, the Netherlands e Laboratory of experimental therapies in oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy f Department of Pediatric oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy g Department of Genetics, Section Metabolic Diagnostics, WKZ, Utrecht, the Netherlands ARTICLE INFO ABSTRACT Keywords: Introduction: A substantial number of patients with neuroblastoma (NB) have increased excretion of catecho- Plasma free metanephrines lamines and metanephrines. Here, we have investigated the diagnostic role of plasma free metanephrines (PFM), Neuroblastoma metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3MT) for NB, the most common extra- Liquid chromatography-tandem mass cranial solid tumour in children. spectrometry Methods: PFM were quantified by using a commercial IVD-CE LC-MS/MS method on a TSQ Quantiva coupled to Diagnosis an Ultimate 3000. The method was further validated on 103 samples from pediatric subjects (54 patients with histologically confirmed NB and 49 age and sex matched controls). Correlations between PFM concentrations with clinical factors were tested.
    [Show full text]
  • The Vanilloid Receptor and Hypertension1
    Acta Pharmacologica Sinica 2005 Mar; 26 (3): 286–294 Invited review The vanilloid receptor and hypertension1 Donna H WANG2 Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI 48825, USA Key words Abstract TRP family; afferent neurons; capsaicin; Mammalian transient receptor potential (TRP) channels consist of six related pro- calcitonin gene-related peptide; substance P; tein sub-families that are involved in a variety of pathophysiological function, and vanilloid receptor; renin-angiotensin- aldosterone system; endothelin, sympathetic disease development. The TRPV1 channel, a member of the TRPV sub-family, is nervous system; salt-sensitive hypertension identified by expression cloning using the “hot” pepper-derived vanilloid com- pound capsaicin as a ligand. Therefore, TRPV1 is also referred as the vanilloid 1 This work was supported in part by National receptor (VR1) or the capsaicin receptor. VR1 is mainly expressed in a subpopula- Institutes of Health (grants HL-52279 and tion of primary afferent neurons that project to cardiovascular and renal tissues. HL-57853) and a grant from the Michigan These capsaicin-sensitive primary afferent neurons are not only involved in the Economic Development Corporation. 2 Correspondence to Donna H WANG, MD. perception of somatic and visceral pain, but also have a “sensory-effector” function. Phn 1-517-432-0797. Regarding the latter, these neurons release stored neuropeptides through a cal- Fax 1-517-432-1326. cium-dependent mechanism via the binding of capsaicin to VR1. The most studied E-mail [email protected] sensory neuropeptides are calcitonin gene-related peptide (CGRP) and substance Received 2004-08-10 P (SP), which are potent vasodilators and natriuretic/diuretic factors.
    [Show full text]
  • Prolactinoma As a Cause of Persistent Hyperprolactinemia in 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency
    Almasseri Z, Nicolas- Jilwan M, Almadani AK, Al-Owain M, Gama R, Sulaiman RA. Journal of Prolactinoma as a Cause of Persistent Hyperprolactinemia in 6-Pyruvoyl-tetrahydropterin Rare Diseases Research synthase Deficiency. J Rare Dis Res Treat. (2020) 5(2): 1-5 & Treatment www.rarediseasesjournal.com Case Series Open Access Prolactinoma as a Cause of Persistent Hyperprolactinemia in 6-Pyruvoyl-tetrahydropterin synthase Deficiency Zainab Almasseri1, Manal Nicolas- Jilwan2, Ahmad Khaled Almadani1, Mohammad Al-Owain1,5, Rousseau Gama3,4, Raashda Ainuddin Sulaiman1,5* 1Department of Medical Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia 2Department of Radiology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia 3Blood sciences, The Royal Wolverhampton NHS trust, Wolverhampton, UK. 4School of Medicine and Clinical Practice, Wolverhampton University, UK 5College of Medicine, Alfaisal University, Riyadh, Saudi Arabia Article Info ABSTRACT Article Notes 6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency results in depletion Received: June 20, 2020 of the brain neuro-transmitters serotonin and dopamine. Since dopamine is the Accepted: July 14, 2020 physiological inhibitor of pituitary prolactin secretion, hyperprolactinemia is *Correspondence: common in patients with PTPS deficiency. Serum prolactin concentrations are Dr. Raashda Ainuddin Sulaiman, Department of Medical used for the monitoring and optimization of L-Dopa therapy. We report three Genetics, MBC: 75, King Faisal Specialist Hospital and adult patients with PTPS deficiency who had persistent hyperprolactinemia Research Centre, PO Box No: 3354, Riyadh, 11211, Saudi unresponsive to high dose L-Dopa therapy, and pituitary imaging confirmed Arabia; Telephone No: 0966 504139266; Fax: +966-11- microadenoma. In the presence of prolactinoma, serum prolactin is an 4424126; Email: [email protected] unreliable tool for treatment monitoring in these patients.
    [Show full text]
  • Frontal Cortical Synaptophysin in Lewy Body Diseases: Relation to Alzheimer’S Disease and Dementia
    J Neurol Neurosurg Psychiatry 1998;64:653–656 653 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.64.5.653 on 1 May 1998. Downloaded from Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer’s disease and dementia L A Hansen, S E Daniel, G K Wilcock, S Love Abstract movement disorder, but up to 40% of patients Objectives—Dementia in Alzheimer’s dis- with Parkinson’s disease eventually become ease correlates closely with loss of neocor- demented.1 DLB is a more recently recognised tical synapses. Similar synaptic loss has clinicopathological entity which accounts for been shown in patients whose Alzheimer’s perhaps 20% of dementia in elderly people.2 It disease is also associated with neocortical is typically associated with mild parkinsonism, and brain stem Lewy bodies. The aim was and usually resting tremor is absent. Both Par- to determine if dementia in Lewy body kinson’s disease and DLB show neuronal loss disease was associated with diminished and gliosis in the substantia nigra, locus concentrations of midfrontal cortex syn- ceruleus, and the nucleus basalis of Meynert, aptophysin. accompanied by single or multiple Lewy Methods—An immunobinding assay was bodies in surviving neurons, and at least some used to measure synaptophysin in post- neocortical Lewy bodies can be found in both mortem samples of midfrontal cortex conditions. The neuropathological abnormali- from 89 patients with Alzheimer’s disease ties associated with dementia in Parkinson’s (ages 59–100, mean 79), 22 with combined disease
    [Show full text]